Antibodies against ECM proteins such as fibulin-3 would have the advantage of excellent accessibility to targets that are outside the tumor cells, as well as the possibility of being delivered locally in the pleural cavity, maximizing intratumoral accumulation. This evidence concerns the gene EFEMP1 and neoplasm.